文献速递肝病

FLIP算法与SAF评分在非酒精性脂肪性肝病中的临床验证

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
PubMed 文献 · J Hepatol · 2019-12-17

采用FLIP算法和SAF评分将患者分类为NASH、NAFL或非NAFLD。结果显示,基于纯形态学的FLIP/SAF分类能识别具有不同临床和生物学严重程度的患者,且疾病活动度与纤维化严重程度相关。

要点

  • FLIP算法定义的NASH患者代谢风险因素更多、胰岛素抵抗更重、转氨酶更高。
  • SAF活动度评分≥3和/或桥接纤维化或肝硬化定义的严重疾病也有类似临床特征。
  • 肝纤维化与NASH或SAF活动度评分强相关,桥接纤维化常与严重活动度共存。

核心结论

  • FLIP算法/SAF评分虽基于形态学,但具有临床相关性,能识别不同临床和生物学严重程度的患者。
  • NAFLD疾病活动度与纤维化严重程度相关。

研究设计与样本

  • 采用FLIP算法和SAF评分对患者进行分类,并分析临床、生化和代谢数据与组织学的关系。

主要发现

  • FLIP算法定义的NASH患者较NAFL患者有更高的代谢风险因素患病率,包括BMI增加、中心性肥胖、血糖和糖化血红蛋白升高。
  • NASH患者胰岛素抵抗更严重,表现为空腹胰岛素和HOMA-IR值更高,且转氨酶水平更高。
  • 严重疾病患者(SAF活动度评分≥3和/或桥接纤维化或肝硬化)与无严重疾病患者相比有类似差异。
  • NASH或严重疾病与BMI和HOMA-IR增加之间存在正线性趋势。
  • 肝纤维化与NASH或SAF定义的活动度评分强相关,显著或桥接纤维化患者绝大多数有NASH,桥接纤维化最常与严重活动度共存。

关键数值与推荐

  • FLIP算法和SAF评分将患者分类为NASH、非NASH NAFLD(NAFL)或非NAFLD。
  • SAF活动度评分评估肝细胞气球样变和小叶内炎症;组织学严重疾病定义为SAF活动度评分≥3和/或桥接纤维化或肝硬化。

临床怎么用

  • FLIP算法/SAF评分可用于临床识别具有不同临床和生物学严重程度的NAFLD患者。
  • 组织学活动度与纤维化严重程度相关,提示在评估NAFLD时需关注纤维化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Histological classifications used to diagnose/stage non-alcoholic fatty liver disease (NAFLD) are based on morphology, with undetermined clinical correlates and relevance. We assessed the clinical relevance of the fatty liver inhibition of progression (FLIP) algorithm and the steatosis, activity, and fibrosis (SAF) scoring system. METHODS: One hundred and forty consecutive patients with suspected NAFLD and a separate validation cohort of 78 patients enrolled in a therapeutic trial, all with central reading of liver biopsy, were included. FLIP and SAF were used to categorize patients with non-alcoholic steatohepatitis (NASH), non-NASH NAFLD (NAFL), or non-NAFLD. The SAF activity score assessed hepatocyte ballooning and lobular inflammation; a histologically severe disease was defined as a SAF activity score of ≥3 and/or bridging fibrosis or cirrhosis. Clinical, biochemical, and metabolic data were analyzed in relation to histology. RESULTS: Patients with NASH according to the FLIP algorithm had a clinical profile distinct from those with NAFL, with a higher prevalence of metabolic risk factors (increased body mass index [BMI], central obesity, serum glucose, and glycated hemoglobin), more severe insulin resistance (fasting insulin and homeostasis model assessment for insulin resistance [HOMA-IR] values), and higher levels of aminotransferases. Similar findings were documented for patients with severe disease vs. those without. Positive linear trends existed between NASH or severe disease and increasing BMI and HOMA-IR. There was a strong association between liver fibrosis and NASH or SAF-defined scores of activity. Patients with either significant or bridging fibrosis overwhelmingly had NASH, and bridging fibrosis most often coexisted with severe activity. CONCLUSIONS: The FLIP algorithm/SAF score, although based on purely morphological grounds, are clinically relevant, as they identify patients with distinct clinical and biological profiles of disease severity. Disease activity in NAFLD is associated with fibrosis severity. LAY SUMMARY: The examination of liver tissue under the microscope (histology) serves to define the type and severity of non-alcoholic fatty liver disease morphologically, and is also used to determine improvement in therapeutic or natural history clinical trials. The FLIP algorithm/SAF classification is a new histological classification well validated on morphological but not clinical grounds. Here, we demonstrate that different disease categories defined by the FLIP/SAF classification correspond to entities of different clinical and biological severity. We also show a strong association between the activity of steatohepatitis (defined histologically) and the amount of fibrotic scar.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol. 2019. PMID: 31862486. doi:10.1016/j.jhep.2019.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。